このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

1日1回の徐放性薬剤で治療された腎移植レシピエントで測定されたタクロリムスのC:D比 (TaC:Drop)

2026年11月3日 更新者:Edward Geissler

腎移植レシピエントに投与された 2 種類の 1 日 1 回タクロリムス製剤 Envarsus® と Advagraf™ の生物学的利用能と実用性を評価するための多施設共同、非盲検、無作為化、二群、並行グループの優位性試験

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

調査の概要

状態

積極的、募集していない

条件

詳細な説明

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.

The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.

Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.

Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.

研究の種類

介入

入学 (実際)

322

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Aachen、ドイツ、52074
        • University Hospital Aachen, Department of General, Visceral and Transplant Surgery
      • Berlin、ドイツ、10117
        • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
      • Bochum、ドイツ、44892
        • Knappschaft Clinic, University Hospital Bochum, Department of Surgery
      • Dresden、ドイツ、01307
        • University Hospital Dresden, Division of Nephrology
      • Hamburg、ドイツ、20251
        • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
      • Hanover、ドイツ、30625
        • Hannover Medical School, Department of General, Visceral and Transplant Surgery
      • Jena、ドイツ、07747
        • University Hospital Jena, Internal Medicine III, Nephrology
      • Mainz、ドイツ、55131
        • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
      • Mannheim、ドイツ、68167
        • University Hospital Mannheim, Medical Clinic V
      • Munich、ドイツ、81377
        • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
      • Münster、ドイツ、48149
        • University Hospital Münster, Medical Clinic D
      • Regensburg、ドイツ、93053
        • University Hospital Regensburg, Department of Nephrology
      • Würzburg、ドイツ、97080
        • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Signed and dated written informed consent
  2. Adult (≥18 years old) male or female
  3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
  4. ABO blood type compatible with the donor kidney
  5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form

Exclusion Criteria:

  1. Multi-organ transplantation
  2. Any previous solid organ transplantation (other than a first kidney allograft)
  3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
  4. Patient and/or donor is positive for active HCV, HBV or HIV infection
  5. History of any malignancy that could not be curatively treated
  6. Ongoing abuse of drugs or alcohol
  7. Signs of advanced liver disease or any signs of liver decompensation
  8. Ongoing uncontrolled systemic infection
  9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
  10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
  11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
  12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
  14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
  15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
  16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Envarsus

Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

他の名前:
  • エンヴァルサス
アクティブコンパレータ:Advagraf

Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.

Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

他の名前:
  • アドバグラフ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
時間枠:12 weeks after kidney transplantation

To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory.

12 weeks after kidney transplantation

二次結果の測定

結果測定
メジャーの説明
時間枠
トラフレベルが目標範囲より低い、目標範囲内、または目標範囲より高い患者の割合
時間枠:腎移植後4日、14日、28日、12週間
腎移植後4日、14日、28日、12週間
タクロリムスのトラフレベルの平均とタクロリムスのトラフレベルの患者間変動(範囲)
時間枠:腎移植後4日、14日、28日、12週間
腎移植後4日、14日、28日、12週間
タクロリムスの平均 1 日用量とタクロリムスの 1 日用量の患者間変動 (範囲)
時間枠:腎移植後4日、14日、28日、12週間
腎移植後4日、14日、28日、12週間
C/D比と1日の投与量の患者内変動
時間枠:時点にわたって測定: 4 日目、14 日目、28 日目、および 12 週目
時点にわたって測定: 4 日目、14 日目、28 日目、および 12 週目
原因による生検の発生率
時間枠:腎移植後12週間
腎移植後12週間
治療が必要な急性拒絶反応の発生率
時間枠:腎移植後12週間
腎移植後12週間
生検で証明された急性拒絶反応のステロイド耐性エピソードの発生率
時間枠:腎移植後12週間と1年
腎移植後12週間と1年
CMVおよびBKV感染の発生率(関連する場合、臓器症状を含む)
時間枠:腎移植後12週間と1年
腎移植後12週間と1年
副作用(AR)の発生率、種類、重症度、重篤度
時間枠:腎移植後12週間と3年
腎移植後12週間と3年
血圧
時間枠:腎移植後12週間と1、2、3年後
腎移植後12週間と1、2、3年後
診断検査が必要な消化器疾患の発生率
時間枠:腎移植後12週間と3年
腎移植後12週間と3年
原発性腎疾患の再発
時間枠:腎移植後12週間と3年
腎移植後12週間と3年
新規DSAの発生率
時間枠:腎移植後1年以内に発見された場合
腎移植後1年以内に発見された場合
グルココルチコステロイド治療の用量と期間
時間枠:腎移植後12週間と1、2、3年後
腎移植後12週間と1、2、3年後
治療中止の発生率と研究期間
時間枠:腎移植から3年後
腎移植から3年後
患者が研究を中止する頻度、期間、および理由
時間枠:腎移植から3年後
腎移植から3年後
Time to reach the first trough level in target range
時間枠:Time period measured in days, assessed within the first 2 weeks after kidney transplantation

Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading

Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Tacrolimus concentration/dose (C/D) ratio
時間枠:4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation

The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site.

4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Treatment failure rate
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause)

12 weeks and 1, 2, 3 years after kidney transplantation
Time to treatment failure after transplantation
時間枠:Measured until 3 years after kidney transplantation

Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause)

Measured until 3 years after kidney transplantation
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition.

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of graft failure
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation

12 weeks and 1, 2, 3 years after kidney transplantation
Mortality rate
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

Mortality rate measures death from any cause

12 weeks and 1, 2, 3 years after kidney transplantation
Graft function measured by eGFR (estimated glomerular filtration rate)
時間枠:4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation

eGFR calculated according to the CKD-EPI formula

4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Incidence rate of delayed graft function
時間枠:Measurable within the first 2 weeks after kidney transplantation

Delayed graft function is defined as the need for more than one episode of dialysis after transplantation

Measurable within the first 2 weeks after kidney transplantation
Incidence rate of primary non-function of the renal allograft
時間枠:Measurable within the first 12 weeks after kidney transplantation

Primary non-function is defined as the necessity for ongoing chronic dialysis

Measurable within the first 12 weeks after kidney transplantation
Incidence of hepatotoxicity
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range

12 weeks and 1, 2, 3 years after kidney transplantation
Incidence of de novo tremor
時間枠:12 weeks and 3 years after kidney transplantation

Incidence and severity of tremor based on medical assessment by the investigator

12 weeks and 3 years after kidney transplantation
Incidence of new onset diabetes mellitus after transplantation (NODAT)
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions

12 weeks and 1, 2, 3 years after kidney transplantation
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
時間枠:12 weeks and 3 years after kidney transplantation

The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients.

12 weeks and 3 years after kidney transplantation
Dose of mycophenolate
時間枠:12 weeks and 1, 2, 3 years after kidney transplantation

Including both mycophenolate mofetil and mycophenolic acid

12 weeks and 1, 2, 3 years after kidney transplantation

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Bernhard Banas, MD、University Hospital Regensburg

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月9日

一次修了 (実際)

2026年2月4日

研究の完了 (推定)

2028年11月1日

試験登録日

最初に提出

2024年2月12日

QC基準を満たした最初の提出物

2024年2月12日

最初の投稿 (実際)

2024年2月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • TaC:Drop
  • 2023-503531-18-00 (その他の識別子:EUCT Number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する